Company Overview:
ZELTIA presents its 4 subsidiary companies:
1) PHARMAMAR: New marine-derived anti-tumor medicines.
2) NOSCIRA: R&D of innovative drugs against nervous system diseases (Alzheimer).
3) SYLENTIS: RNAi-based drugs for treating ophthalmic and digestive diseases.
4) GENOMICA: Automated molecular diagnostics for infectious diseases.DNA identification, tech-transfer.
Brand Names:
PRODUCTS: Oncology: YONDELIS® Molecular diagnostics: CLART® FluAVir, CLART® HPV2, CLART® ENTHERPEX, CLART® PneumoVir, CLART® Metabone, CLART® Plataformas. PIPELINE: Cancer R&D: YONDELIS®, APLIDIN®, ZALYPSIS®, IRVALEC®, PM01183. Nervous System R&D: NYPTA®, NP61. siRNA Ophthalmics R&D: SYL040012.